Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, has released its Appendix 4C Quarterly Cash Flow Report for Q4 FY24, ending June 30, 2024. The report highlights positive interim data from the ATH434-202 Phase 2 clinical trial, which showed improvement in activities of daily living and stable or improved neurological symptoms in some patients with advanced Multiple System Atrophy (MSA). The company's bioMUSE Natural History Study continues to inform the development of ATH434 by characterizing early-stage MSA. Alterity presented multiple data sets at the World Orphan Drug Congress and the American Academy of Neurology Annual Meeting. As of June 30, 2024, Alterity reported a cash balance of A$12.6M, with operating cash outflows for the quarter totaling A$5.6M. The company's ATH434-201 Phase 2 clinical trial in early-stage MSA...Show More

Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, has released its Appendix 4C Quarterly Cash Flow Report for Q4 FY24, ending June 30, 2024. The report highlights positive interim data from the ATH434-202 Phase 2 clinical trial, which showed improvement in activities of daily living and stable or improved neurological symptoms in some patients with advanced Multiple System Atrophy (MSA). The company's bioMUSE Natural History Study continues to inform the development of ATH434 by characterizing early-stage MSA. Alterity presented multiple data sets at the World Orphan Drug Congress and the American Academy of Neurology Annual Meeting. As of June 30, 2024, Alterity reported a cash balance of A$12.6M, with operating cash outflows for the quarter totaling A$5.6M. The company's ATH434-201 Phase 2 clinical trial in early-stage MSA is ongoing, with the Data Monitoring Committee recommending continuation without modification. The trial is expected to complete in November 2024, with topline results anticipated by January 2025. Alterity also shared insights into ATH434's potential for treating Parkinson's Disease, with positive effects observed in hemiparkinsonian macaques. The company remains committed to its mission of developing treatments for neurodegenerative diseases and is well-positioned to continue its clinical programs with its current funding.